EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality

Yadira Lobaina, Rong Chen, Edith Suzarte, Panchao Ai, Vivian Huerta, Alexis Musacchio, Ricardo Silva, Changyuan Tan, Alejandro Martín, Laura Lazo iD, Gerardo Guillén-Nieto iD, Ke Yang iD und 2 weitere

Viruses · 2024

DOI: 10.3390/v16030418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Yadira Lobaina und 13 weiteren Autor:innen. Beteiligte Einrichtung: Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China. Hauptthemen laut MEDLINE: COVID-19, Vaccines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, Hunan Provincial Base for Scientific and Technological Innovation Cooperation, The Science and Technology Innovation Program of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the rapid development of vaccines against COVID-19, they have important limitations, such as safety issues, the scope of their efficacy, and the induction of mucosal immunity. The present study proposes a potential component for a new generation of vaccines. The recombinant nucleocapsid (N) protein from the SARS-CoV-2 Delta variant was combined with the ODN-39M, a synthetic 39 mer unmethylated cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN), used as an adjuvant. The evaluation of its immunogenicity in Balb/C mice revealed that only administration by intranasal route induced a systemic cross-reactive, cell-mediated immunity (CMI). In turn, this combination was able to induce anti-N IgA in the lungs, which, along with the specific IgG in sera and CMI in the spleen, was cross-reactive against the nucleocapsid protein of SARS-CoV-1. Furthermore, the nasal administration of the N + ODN-39M preparation, combined with RBD Delta protein, enhanced the local and systemic immune response against RBD, with a neutralizing capacity. Results make the N + ODN-39M preparation a suitable component for a future intranasal vaccine with broader functionality against Sarbecoviruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19VaccinesAnimalsMiceHumansAdministration, IntranasalNucleocapsid ProteinsVaccines, CombinedSARS-CoV-2COVID-19 VaccinesImmunity, MucosalAdjuvants, ImmunologicAntibodies, ViralAntibodies, Neutralizing

Stichwörter der Autor:innen

ODNSARS-CoV-2bivalent vaccinebroad vaccinecell-mediated immunityintranasalneutralizing Abs

Substanzen

Nucleocapsid ProteinsVaccines, CombinedCOVID-19 VaccinesVaccinesAdjuvants, ImmunologicAntibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.
  • R&D Department, Yongzhou Zhong Gu Biotechnology Co., Ltd., Yangjiaqiao Street, Lengshuitan District, Yongzhou 425000, China.
  • Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China.
  • CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
  • BCF: R&D Section, Representative Office BCF in China, Jingtai Tower, No. 24 Jianguomen Wai Street, Chaoyang District, Beijing 100022, China.

ORCID-Profile: Laura Lazo, Gerardo Guillén-Nieto, Ke Yang

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • Hunan Provincial Base for Scientific and Technological Innovation Cooperation
  • The Science and Technology Innovation Program of Hunan Province
  • Hunan Provincial Innovative Construction Program
  • National key R&D program of China
  • PNCT CITMA

Zitieren

APA

Lobaina, Y., Chen, R., Suzarte, E., Ai, P., Huerta, V., Musacchio, A., Silva, R., Tan, C., Martín, A., Lazo, L., Guillén-Nieto, G., Yang, K., Perera, Y., & Hermida, L. (2024). The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality. Viruses. https://doi.org/10.3390/v16030418

Vancouver

Lobaina Y, Chen R, Suzarte E, Ai P, Huerta V, Musacchio A, et al. The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality. Viruses. 2024. doi:10.3390/v16030418

BibTeX
@article{Lobaina2024,
  author = {Lobaina, Yadira and Chen, Rong and Suzarte, Edith and Ai, Panchao and Huerta, Vivian and Musacchio, Alexis and Silva, Ricardo and Tan, Changyuan and Martín, Alejandro and Lazo, Laura and Guillén-Nieto, Gerardo and Yang, Ke and Perera, Yasser and Hermida, Lisset},
  title = {The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16030418}
}
Kostenlos starten →